Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
ConditionJuvenile Idiopathic Arthritis (JIA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
Eligibility criteria
Qualifiers
Greater than or equal to 16 years-old
Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
No-opposition to the research
Patient with health insurance
Disqualifiers
Patient under curatorship or guardianship
Patient receiving french state medical aid
Trial design
Treatments tested in this trial
- Blood sample
- Joint puncture
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator
Source ClinicalTrials.gov